Pancreatic Cancer Market size is estimated to surpass USD 36 Billion by the end of 2036, growing at a CAGR of 18% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of the pancreatic cancer was over USD 6 Billion. The growth of the market can be attributed to the rising prevalence of cancer cases among people across the world. It is expected that there will be nearly 40 million new cancer cases across the globe by 2040, according to the Pan American Health Organization.
The changing lifestyle habits and adoption of alcohol are estimated to boost market growth across the world. The increasing prevalence of obesity is also estimated to drive market growth around the world. More than 1 billion population across the globe are suffering from obesity with over 600 million adults, 40 million children, and more than 300 million adolescents.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~ 18 % |
|
Base Year Market Size (2023) |
~ USD 6 Billion |
|
Forecast Year Market Size (2036) |
~ USD 36 Billion |
|
Regional Scope |
|
Type (Chemotherapy, Targeted Therapy)
The chemotherapy segment is estimated to account for 55% share of the global pancreatic cancer market in the year 2036. The increasing use of chemotherapy and targeted therapy for cancer cell isolation in tumor formation is estimated to propel the market segment growth as per the market analysis. The rising presence of competent practitioners and increasing medical facilities for providing chemotherapy across the world are expected to drive market segment growth in the coming years. More than 26% of people across the UK are estimated to have chemotherapy as the primary treatment for pancreatic cancer as of 2020.
Affected Area (Exocrine, Endocrine)
The exocrine segment is expected to hold 60% of the revenue share by 2036. The pancreas is mostly composed of exocrine cells compared to endocrine cells in the body is estimated to drive the market segment growth. The growth of the segment is attributed to the increasing prevalence of exocrine cancers. More than 90% of pancreatic cancers across the world are exocrine tumours as of estimations in 2022. Cancer in the ducts affects the exocrine cells of the pancreas causing exocrine cancer and is estimated to drive market growth across the world.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
Affected Areas |
|
|
End User |
|
North American Market Forecast
The pancreatic cancer market in the North America is projected to be the largest with a share of about 32% by the end of 2036. The growth of the market can be attributed majorly to the increasing adoption of new technologies for the treatment of cancer cases in the region. In addition, there has been a rise in the number of clinics providing chemotherapy in the countries such as the United States, that is further adding opportunities for the market’s growth in the region.
Asia Pacific Market Statistics
The Asia Pacific region is projected to hold around 28% share of the global pancreatic cancer market by 2036. The increasing number of diagnostic tests occurring in the region with a high prevalence rate is also driving the market growth. The rising pharmaceutical companies across the region with clinical trials to develop new drugs are estimated to hike the market growth in the Asia Pacific region.
Author Credits: Radhika Gupta, Shivam Bhutani
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?